Navigation Links
Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections
Date:11/4/2008

Success of Zyvox and Cubicin is Driven Strongly by Agents' Excellent Activity Against MRSA, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., Nov. 4 /PRNewswire/ --Arlington Medical Resources (AMR) and Decision Resources find that with the rising incidence of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), an overwhelming majority of surveyed physicians indicate that the most important attribute influencing antibiotic selection in skin and skin structure infections (SSSIs) is activity against MRSA. Other factors that influence drug selection include an agent's skin penetration and its ability to avoid the development of resistant pathogens.

"Physicians we surveyed also indicate that the two most important factors that influence hospital prescribing for SSSIs are recommendations from infectious disease consults and the Infectious Diseases Society of America (IDSA) guidelines. Clinicians treating patients with SSSIs look to these specialists and guidelines for direction when managing SSSI patients," stated John Lebbos, M.D., vice president of infectious diseases at Decision Resources.

The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections also finds that surveyed physicians state that the success of Pfizer's Zyvox and Cubist Pharmaceuticals' Cubicin is driven strongly by these agents' excellent activity against MRSA. Vancomycin remains the most commonly prescribed agent for empiric coverage of MRSA, and its use is largely driven by familiarity and local hospital guidelines. In contrast, surveyed physicians indicate that use of Zyvox and Cubicin is driven by product attributes, namely their excellent activity against MRSA activity.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

2008 Hospital Anti-Infectives Insight Series reports include:

-- Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia

-- Hospital Anti-Infectives Insight Series: Skin & Skin Structure

Infections

-- Hospital Anti-Infectives Insight Series: U.S. Antibiotic Usage Patterns

and Drivers in the ICU Setting

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources; Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tufts Nelson a leader on Physical Activity Guidelines advisory committee
2. Vigorous activity protects against breast cancer
3. YMCA of the USA Supports New National Physical Activity Guidelines
4. ACSM, AHA Support Federal Physical Activity Guidelines
5. Walking forum report shows need to expand physical activity in schools
6. New way to control protein activity could lead to cancer therapies
7. Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue
8. Social Network for Affordable Health Care Supporters Stimulates a New Level of Interactivity and Dialogue
9. Banque Centrale Populaire Consolidates Activity Abroad With New Trade Finance Solutions From Misys
10. Gene Activity May Explain Deadlier Breast Cancers Among Younger Women
11. Seizures in newborns can be detected with small, portable brain activity monitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Hills, California (PRWEB) , ... February 17, 2017 ... ... info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon Dr. ... subcutaneous fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance ... change designed to further positively impact the health and wellness of our community ... considered it our duty to seriously consider releasing our assets beyond our 5% ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ... manufacturers should be asking before selecting an FDA approval pathway? , How ...
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/16/2017)... -- Absorption Systems, a global leader in nonclinical testing ... announce that its Chief Operating Officer, Sid Bhoopathy ... the 2017 Executive Management Award. The award is sponsored ... for their creative management vision, leadership philosophy, innovative strategy ... is on March 8, 2017 at the Ballroom at ...
(Date:2/16/2017)... 2017 DaVita Inc. (NYSE: DVA ) ... 31, 2016. Net income attributable to DaVita ... was $158 million, or $0.80 per share and $880 million, ... income attributable to DaVita Inc. for the quarter and year ... was $192 million, or $0.98 per share, and $789 million, ...
Breaking Medicine Technology: